Asia Oceania Journal of Nuclear Medicine and Biology

Asia Oceania Journal of Nuclear Medicine and Biology

Physiological myocardial 18F-FDG uptake pattern in oncologic PET/CT: comparison with findings in cardiac sarcoidosis

Document Type : Original Article

Authors
Takashi Norikane 1
Yuka Yamamoto 1
Yasukage Takami 1
Katsuya Mitamura 1
Takuya Kobata 1
Yukito Maeda 1
Takahisa Noma 2
Yoshihiro Nishiyama 1
1 Department of Radiology, Faculty of Medicine, Kagawa University, Kagawa, Japan
2 Department of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
10.22038/aojnmb.2023.70254.1490
Abstract
Objective(s): Physiological myocardial 18F-fluorodeoxyglucose (18F-FDG) uptake in oncologic positron emission tomography (PET)/computed tomography (CT) is commonly observed with multiple variations under clinical fasting conditions. The purpose of the present study was to evaluate physiological myocardial 18F-FDG uptake pattern by comparing with the results in cardiac sarcoidosis.
Methods: A total of 174 examinations in 174 patients without cardiac disease and 27 examinations in 17 patients with cardiac sarcoidosis were performed. The polar map images generated from 18F-FDG PET/CT data were visually assessed as “basal-ring,” “focal,” and “focal on diffuse” patterns. Semi-quantitative analysis was also performed using the regional relative 18F-FDG uptake (% uptake).
Results: On visual analysis, the “focal on diffuse” pattern was the most common in both examinations (43% and 59%, respectively). The physiological % uptake in the lateral and basal septal walls tended to be higher. Subgroup analysis showed significantly higher uptake in the mid-wall and left circumflex territory. In cardiac sarcoidosis patients, there was a significant difference only between segments 2 and 15 (p=0.04). No significant differences were observed between the base-mid-apical territory and coronary artery branch territory.
Conclusion: High 18F-FDG uptake in the basal septal walls is likely to be observed as both physiological uptake in patients without cardiac disease and pathological uptake in patients with cardiac sarcoidosis.
Keywords
18F-FDG
PET
Physiological uptake
Subjects
  1. Saponara M, Ambrosini V, Nannini M, Gatto L, Astolfi A, Urbini M, et al. 18F-FDG-PET/CT imaging in cardiac tumors: illustrative clinical cases and review of the literature. Ther Adv Med Oncol. 2018; 10: 17588359 18793569.
  2. Judson MA, Costabel U, Drent M, Wells A, Maier L, Koth L, et al. The WASOG sarcoidosis organ assessment instrument: An update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis. 2014; 31(1):19–27.
  3. Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014; 11(7):1304–23.
  4. Ozawa K, Funabashi N, Daimon M, Takaoka H, Takano H, Uehara M, et al. Determination of optimum periods between onset of suspected acute myocarditis and 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of inflammatory left ventricular myocardium. Int J Cardiol. 2013; 169(3):196–200.
  5. Lopaschuk GD, Stanley WC. Glucose metabolism in the ischemic heart. Circulation. 1997; 95(2): 313–5.
  6. Yoshinaga K, Miyagawa M, Kiso K, Ishida Y. Japanese guidelines for cardiac sarcoidosis.Ann Nucl Cardiol. 2017; 3(1):121–4.
  7. Terasaki F, Yoshinaga K. New guidelines for diagnosis of cardiac sarcoidosis in Japan. Ann Nucl Cardiol. 2017; 3(1):2–45.
  8. The Japanese Circulation Society (JCS). Guidelines for the diagnosis and treatment of cardiac sarcoidosis (JCS 2016) (Chair: Fumio Terasaki). Http: //www. J-circ. or. jp/guideline/pdf/JCS2016_terasaki_h.pdf, 2017. Accessed 18 Jan 2023.
  9. Youssef G, Beanlands RS, Birnie DH, Nery PB. Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment. Heart. 2011; 97(24):2078–87.
  10. Diagnostic standard and guideline for sarcoidosis-2015. http://www.jssog.com/ www/top/shindan/shindan2-1new.html. Accessed 1 Jul 2016.
  11. Kumita S, Yoshinaga K, Miyagawa M, Momose M, Kiso K, Kasai T, et al. Recommendations for 18F-fluorodeoxy-glucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis—2018 update: Japanese Society of Nuclear Cardiology recommendations. J Nucl Cardiol. 2019; 26(4):1414–33.
  12. Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Annu Rev Physiol. 1974; 36:413–59.
  13. Manabe O, Yoshinaga K, Ohira H, Masuda A, Sato T, Tsujino I, et al. The effects of 18-h fasting with low-carbohydrate diet pre-paration on suppressed physiological myocardial (18)F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol. 2016; 23: 244–52.
  14. Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006; 47(5):885–95.
  15. Maurer AH, Burshteyn M, Adler LP, Steiner RM. How to differentiate benign versus malignant cardiac and paracardiac 18F-FDG uptake at oncologic PET/CT. Radiographics. 2011; 31(5):1287–305.
  16. Tamaki N, Yonekura Y, Kawamoto M, Magata Y, Sasayama S, Takahashi N, et al. Simple quantification of regional myo-cardial uptake of fluorine-18-deoxyglucose in the fasting condition. J Nucl Med. 1991; 32(11):2152–7.
  17. Fukuchi K, Ohta H, Matsumura K, Ishida Y. Benign variations and incidental abnormalities of myocardial FDG uptake in the fasting state as encountered during routine oncology positron emission tomography studies. Br J Radiol. 2007; 80(949):3–11.
  18. Inglese E, Leva L, Matheoud R, Sacchetti G,Secco C, Gandolfo P, et al. Spatial and temporal heterogeneity of regional myo-cardial uptake in patients without heart disease under fasting conditions on repeated whole-body 18F-FDG PET/CT. J Nucl Med. 2007;48(10):1662–9.
  19. Thut DP, Ahmed R, Kane M, Djekidel M. Variability in myocardial metabolism on serial tumor 18F-FDG PET/CT scans. Am J Nucl Med Mol Imaging. 2014; 4(4):346–53.
  20. Valantine H, McKenna WJ, Nihoyannopoulos P, Mitchell A, Foale RA, Davies MJ, et al. Sarcoidosis: a pattern of clinical and morphological presentation. Br Heart J. 1987; 57(3):256–63.
  21. Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group I) and review of 78 previously described necropsy patients (group II). Am J Med. 1977; 63(1): 86–108.
  22. Christopoulos G, Jouni H, Acharya GA, Blauwet LA, Kapa S, Bois J, et al. Suppressing physiologic 18-fluorodeoxy-glucose uptake in patients undergoing positron emission tomography for cardiac sarcoidosis: The effect of a structured patient preparation protocol. J Nucl Cardiol. 2021; 28(2):661–71.
  23. Hansen CL, Goldstein RA, Akinboboye OO, Berman DS, Botvinick EH, Churchwell KB, et al. Myocardial perfusion and function: single photon emission computed tomo-graphy. J Nucl Cardiol. 2007; 14(6): e39–60.
  24. Gropler RJ, Siegel BA, Lee KJ, Moerlein SM, Perry DJ, Bergmann SR, et al. Non-uniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med. 1990; 31(11): 1749–56.
  25. Fathala A, Abouzied M, AlSugair AA. Cardiac and pericardial tumors: A potential application of positron emission tomography-magnetic resonance imaging. World J Cardiol. 2017; 9(7):600–8.
  26. Lin EC. Isolated papillary muscle uptake on FDG PET/CT. Clin Nucl Med. 2007; 32(1): 76–8.
  27. Jingu K, Kaneta T, Nemoto K, Ichinose A, Oikawa M, Takai Y, et al. The utility of 18F-fluorodeoxyglucose positron emission tomography for early diagnosis of radiation-induced myocardial damage. Int J Radiat Oncol Biol Phys. 2006; 66(3):845–51.
  28. Maurer AH, Burshteyn M, Adler LP, Gaughan JP, Steiner RM. Variable cardiac 18FDG patterns seen in oncologic positron emission tomography computed tomography: importance for differentiating normal physiology from cardiac and paracardiac disease. J Thorac Imaging. 2012; 27(4):263–8.
  29. Nose H, Otsuka H, Otomi Y, Terazawa K, Takao S, Iwamoto S, et al. The physiological uptake pattern of 18F-FDG in the left ventricular myocardium of patients without heart disease. J Med Invest. 2014; 61(1-2): 53–8.
  30. Scholtens AM, Verberne HJ, Budde RPJ, Lam MGEH. Additional heparin preadminis-tration improves cardiac glucose metabolism suppression over low-carbo-hydrate diet alone in 18F-FDG PET imaging. J Nucl Med. 2016; 57(4):568–73.
  31. Yamagishi H, Shirai N, Takagi M, Yoshiyama M, Akioka K, Takeuchi K, et al. Identification of cardiac sarcoidosis with 13N-NH3/18F-FDG PET. J Nucl Med. 2003; 44(7):1030–1036.
  32. Manabe O, Ohira H, Hirata K, Hiyashi S, Naya M, Tsujino I, et al. Use of 18F-FDG PET/CT texture analysis to diagnose cardiac sarcoidosis. Eur J Nucl Med Mol Imaging. 2019; 46(6):1240–7.
  33. Schildt JV, Loimaala AJ, Hippeläinen ET, Ahonen AA. Heterogeneity of myocardial 2-[18F]fluoro-2-deoxy-D-glucose uptake is a typical feature in cardiac sarcoidosis: a study of 231 patients. Eur Heart J Cardiovasc Imaging. 2018; 19(3):293–8.
  34. Sperry BW, Tamarappoo BK, Oldan JD, Javed O, Culver DA, Brunken R, et al. Prognostic impact of extent, severity, and heterogeneity of abnormalities on 18F-FDG PET scans for suspected cardiac sarcoidosis. JACC: Cardiovasc Imaging. 2018; 11 (2 Pt 2):336–45.
  35. Kaneta T, Hakamatsuka T, Takanami K, Yamada T, Takase K, Sato A, et al. Evaluation of the relationship between physiological FDG uptake in the heart and age, blood glucose level, fasting period, and hospitali-zation. Ann Nucl Med. 2006; 20(3): 203-8.
  36. Becker MMC, Arruda GFA, Berenguer DRF, Buril RO, Cardinale D, Brandão SCS. Anthracycline cardiotoxicity: current methods of diagnosis and possible role of 18F-FDG PET/CT as a new biomarker. Cardiooncology. 2023; 9(1):17.
  37. Keramida K, Farmakis D, Bingcang J, Sulemane, S., Sutherland, S., Bingcang, R. A., et al. Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients. Eur J Heart Fail. 2019; 21(4):529-35.
  38. Sarocchi M, Bauckneht M, Arboscello E, Capitanio S, Marini C, Morbelli S, et al. An increase in myocardial 18-fluorodeoxy-glucose uptake is associated with left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with anthracycline. J Transl Med. 2018; 16(1): 295.
  39. Kim, J, Cho, S. G, Kang, S. R, Yoo, S. W, Kwon, S. Y, Min, J. J, et al. Association between FDG uptake in the right ventricular myocardium and cancer therapy-induced cardiotoxicity. J Nucl Cardiol. 2020; 27(6):2154-63.
Asia Oceania Journal of Nuclear Medicine and Biology
Volume 12, Issue 1
January 2024
Pages 1-10